Acurx Pharmaceuticals, Inc.
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $4.6Mattributed |
|---|---|
| Latest round | Funding round, $4.6M, 2026-04-15attributed |
| Founded | 2017 |
| Headquarters | STATEN ISLAND, NY |
| Industry | pharmaceuticals |
| Stage | unknown |
| Website | acurx.com |
Acurx Pharmaceuticals is a clinical-stage biopharma developing a new class of antibiotics targeting bacteria listed as priority pathogens by the WHO, CDC, and FDA. It serves patients with serious resistant infections, with lead candidate ibezapolstat in trials. Its differentiator is a novel DNA polymerase IIIC inhibition mechanism.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-15 | Funding round | $4.6M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $4.6M | attributed | sec-edgar named as publisher. No document URL on file. |
| Total raised $4.6M | attributed | sec-edgar named as publisher. No document URL on file. |
| Company existence | self-reported | acurx.com, read 2026-05-07 |
| Description | self-reported | acurx.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $4.6M, 2026-04-15 → Funding round, $4.6M, 2026-04-15, sec-edgar, No document URL on file | Latest round | seed, $4.6M, 2026-04-15 → Funding round, $4.6M, 2026-04-15 | sec-edgar, No document URL on file |
Records begin 2026-09-24. All changes